Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 1 1

Status

Completed 15Withdrawn 3Terminated 3Recruiting 2Not yet recruiting 2Active not recruiting 2

Sponsor Class

OTHER 7INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia 2Recurrence 1Neoplasm, Residual 1Bites and Stings 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × blinatumomab × Clear all
NCT06063317 2026-03-06

OASIS

Imugene Limited

Phase 1 Terminated
25 enrolled

Bites and Stings

NCT04506086 2025-05-18

Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 4 Terminated
10 enrolled 12 charts
LymphoidOther hematologic neoplasm

Leukemia, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02013167 2024-03-05

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Terminated
405 enrolled 27 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡